Clinical Trial Update: Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan [Phase 4]

View source ↗

Summary

Phase 4 study evaluating sivelestat sodium hydrate for acute lung injury associated with systemic inflammatory response syndrome in Japan has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Systemic Inflammatory Response Syndrome

Drugs mentioned

• Sivelestat sodium hydrate (sivelestat)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Acute Lung Injury, Systemic Inflammatory Response Syndrome | Phase 4 | Status: COMPLETED